CRS, ICANS, and SAEs reported after infusion (N = 18)
| Variable . | Grade 1-2 . | Grade 3 . | Grade 4 . | Grade 5 . | All grades . |
|---|---|---|---|---|---|
| AEs related to CT103A | |||||
| CRS | 13 (72.2) | 3 (16.7) | 1 (5.6) | — | 17 (94.4) |
| ICANS | — | — | — | — | 0 (0.0) |
| SAEs recorded during the first 8 weeks’ postinfusion | |||||
| CRS | — | — | 1 (5.6) | — | 1 (5.6) |
| Coagulation disorder | 1 (5.6) | — | — | — | 1 (5.6) |
| Hypoxemia | — | — | 1 (5.6) | — | 1 (5.6) |
| Pleuritis | 1 (5.6) | — | — | — | 1 (5.6) |
| Prolonged cytopenia | 2 (11.1) | 1 (5.6) | — | — | 3 (16.7) |
| Pulmonary infection | — | 1 (5.6) | — | 1 (5.6) | 2 (11.1) |
| SAEs recorded during long-term follow-up (from 8 weeks’ postinfusion to cutoff date) | |||||
| Appendicitis | — | 1 (5.6) | — | — | 1 (5.6) |
| Cellulitis | — | 1 (5.6) | — | — | 1 (5.6) |
| Herpes zoster | — | 2 (11.1) | — | — | 2 (11.1) |
| Pulmonary infection | 1 (5.6) | 1 (5.6) | — | — | 2 (11.1) |
| Septic shock | — | — | — | 1 (5.6) | 1 (5.6) |
| Variable . | Grade 1-2 . | Grade 3 . | Grade 4 . | Grade 5 . | All grades . |
|---|---|---|---|---|---|
| AEs related to CT103A | |||||
| CRS | 13 (72.2) | 3 (16.7) | 1 (5.6) | — | 17 (94.4) |
| ICANS | — | — | — | — | 0 (0.0) |
| SAEs recorded during the first 8 weeks’ postinfusion | |||||
| CRS | — | — | 1 (5.6) | — | 1 (5.6) |
| Coagulation disorder | 1 (5.6) | — | — | — | 1 (5.6) |
| Hypoxemia | — | — | 1 (5.6) | — | 1 (5.6) |
| Pleuritis | 1 (5.6) | — | — | — | 1 (5.6) |
| Prolonged cytopenia | 2 (11.1) | 1 (5.6) | — | — | 3 (16.7) |
| Pulmonary infection | — | 1 (5.6) | — | 1 (5.6) | 2 (11.1) |
| SAEs recorded during long-term follow-up (from 8 weeks’ postinfusion to cutoff date) | |||||
| Appendicitis | — | 1 (5.6) | — | — | 1 (5.6) |
| Cellulitis | — | 1 (5.6) | — | — | 1 (5.6) |
| Herpes zoster | — | 2 (11.1) | — | — | 2 (11.1) |
| Pulmonary infection | 1 (5.6) | 1 (5.6) | — | — | 2 (11.1) |
| Septic shock | — | — | — | 1 (5.6) | 1 (5.6) |
Data are presented as no. (%).